Several outlets report trial results for daraxonrasib, a once-daily pill used with chemotherapy, that show major tumour shrinkage in some patients with advanced pancreatic cancer. The reporting says in a small share of participants tumours become undetectable, prompting comparisons to a “closest thing to a cure,” though the outcomes described are based on trial follow-up rather than a definitive cure for all.
The Guardian, BBC News and Metro highlight that researchers report tumour control rates close to complete for most trial participants, with a disease control rate described as “nearly all” or around 90% and a subset with complete responses. The Independent also stresses the wider context of pancreatic cancer’s burden in the UK, while noting that the drug previously made headlines in May for extending survival compared with chemotherapy alone.
While the outlets broadly agree on the central trial message—better tumour outcomes when daraxonrasib is combined with chemotherapy—coverage differs in emphasis. Some focus on the “biggest breakthrough” framing, others lead with the number of patients whose cancer is undetectable, and a few add mechanistic or regulatory context details based on the same trial reports.